Details of Viral Vaccine
This Viral vaccine card gives comprehensive information about each vaccine.
| Detailed Information | |
|---|---|
| ID | 10175 |
| Vaccine Name | MV-014-212 |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Phase 1 |
| Manufacturer | Meissa Vaccines Inc. |
| Year of Manufacturing | 2021 |
| Manufacturing Country | USA |
| Age | 18 - 69 years |
| Dosage | 2 doses 35 days apart |
| Administration Route | Intranasal |
| Adjuvant | NA |
| Target Strain | Spike protein of SARS-CoV-2 virus |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT04798001 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT04798001?term=covid-19+vaccine&draw=2 |
| Additional Links | NA |